The next step in preimplantation genetic screening.
Embryo quality is crucial for pregnancy success in IVF, and chromosomal normality is directly linked to embryo quality.
Chromosomal abnormalities can be identified through Preimplantation Genetic Testing for Aneuploidy (PGT-A), formerly known as Preimplantation Genetic Screening (PGS).
Embryo46, the new generation of PGT-A testing, goes beyond standard aneuploidy detection, providing a more accurate determination of chromosomal abnormalities in embryos.
Increased Pregnancy Rate
Reduced Miscarriage Rate
Enhanced Genetic Abnormality Detection
Improved Blastocyst Utilization Rate
Embryo46 offers advanced PGT-A capabilities that provide comprehensive insights into embryo health.
Checks if embryos have the correct number of chromosomes. Too many or too few can lead to failed implantation, miscarriage, or medical conditions like Down syndrome or Turner syndrome.
Looks for small missing or extra pieces of chromosomes. These can affect embryo development, leading to failed implantation, miscarriage, or genetic disorders.
Unique to Embryo46, this measures the total number of chromosome sets in an embryo. Normal embryos have two sets (diploidy), but some may have one set (haploidy) or three sets (triploidy), which will lead to implantation failure or miscarriage
Unique to Embryo46, this checks if all chromosomes in an embryo come from one parent instead of one from each parent. This can lead to failed implantation, miscarriage, or genetic disorders.
Embryo46 provides enhanced sequencing resolution that can better detect smaller CNV fragments for chromosomal abnormalities. This allows for the selection of embryos that can result in higher pregnancy rates and fewer genetic complications.
Unlike traditional PGT-A, Embryo46 also detects haploidy (one set of chromosomes) and triploidy (three sets of chromosomes), which have been shown to cause miscarriage at a rate of 15-18% (Mutia K, et al. 2019). Selecting embryos with the correct set of two chromosomes (diploidy) increases successful pregnancy rates while reducing the risk of genetic abnormalities.
UPD occurs in approximately 0.05% of newborns, where both sets of chromosomes are inherited from one parent. This can lead to various imprinted genetic disorders, including Angelman syndrome and Prader-Willi syndrome.
A recent study has shown that our PGT-A test, Embryo46, led to higher successful pregnancy rates, higher live birth rates, and lower miscarriage rates.
Preimplantation genetic screening (PGS) can be beneficial for any IVF patient, but patients who meet one or more of the following conditions have the most to gain from Embryo46:
Download our brochure from the link below:
Do you have more questions? Curious about how Embryo46 can increase your clinic's success rate? Head over to our Contact page, or set up a learning session with our Global Business Development Directory Tiffany Wang by reaching out directly: [email protected]
